Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN

Cited by (525)

Items 101–200 of 525

1. Defining E3 ligase–substrate relationships through multiplex CRISPR screening
   Richard T. Timms, Elijah L. Mena, Yumei Leng, Mamie Z. Li, Iva A. Tchasovnikarova, Itay Koren, Stephen Joseph Elledge · 2023 · Nature Cell Biology
2. Evolution of Cereblon-Mediated Protein Degradation as a Therapeutic Modality
   Philip P. Chamberlain, Laura Akullian D’Agostino, J. Michael Ellis, Joshua D. Hansen, Mary E. Matyskiela, Joseph J. McDonald, Jennifer R. Riggs, Lawrence G. Hamann · 2019 · ACS Medicinal Chemistry Letters
3. Induced protein degradation for therapeutics: past, present, and future
   Hojong Yoon, Justine C. Rutter, Yen-Der Li, Benjamin L. Ebert · 2024 · Journal of Clinical Investigation
4. Emerging role of ZBTB7A as an oncogenic driver and transcriptional repressor
   Sanjay Gupta, Atul Kumar Singh, Kumari Sunita Prajapati, Prem Prakash Kushwaha, Mohd Shuaib, Shashank Kumar · 2020 · Cancer Letters
5. Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation
   Yamanaka, Satoshi, Furihata, Hirotake, Yanagihara, Yuta, Taya, Akihito, Nagasaka, Takato, Usui, Mai, Nagaoka, Koya, Shoya, Yuki, Nishino, Kohei, Yoshida, Shuhei et al. · 2023 · Nature Communications
6. Transcription factor Ikzf1 associates with Foxp3 to repress gene expression in Treg cells and limit autoimmunity and anti-tumor immunity
   Kenji Ichiyama, Jia Long, Yusuke Kobayashi, Yuji Horita, Takeshi Kinoshita, Yamami Nakamura, Chizuko Kominami, Katia Georgopoulos, Shimon Sakaguchi · 2024 · Immunity
7. Computer-Aided Drug Discovery for Undruggable Targets
   Qi Sun, Hanping Wang, Juan Xie, Liying Wang, Junxi Mu, Junren Li, Yuhao Ren, Luhua Lai · 2025 · Chemical Reviews
8. The rise of degrader drugs
   Mingxing Teng, Nathanael S. Gray · 2023 · Cell chemical biology
9. Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs
   Adam Samuel Sperling, Michael W. Burgess, Hasmik Keshishian, Jessica A. Gasser, Shruti Bhatt, Max Jan, Mikolaj Michal Slabicki, Rob S. Sellar, Emma C. Fink, Peter Grant Miller et al. · 2019 · Blood
10. Phenyl Dihydrouracil: An Alternative Cereblon Binder for PROTAC Design
    Jamie Jarusiewicz, Satoshi Yoshimura, Anand Mayasundari, Marisa Actis, Anup Aggarwal, Kevin M. McGowan, Lei Yang, Yong Li, Xiang Fu, Vibhor Mishra et al. · 2023 · ACS Medicinal Chemistry Letters
11. Development of PDE6D and CK1α Degraders through Chemical Derivatization of FPFT-2216
    Teng, Mingxing, Lu, Wenchao, Donovan, Katherine A., Sun, Jialin, Krupnick, Noah M., Nowak, Radosław P., Li, Yen-Der, Sperling, Adam S., Zhang, Tinghu, Ebert, Benjamin L. et al. · 2022 · Journal of Medicinal Chemistry
12. Targeted protein degradation in cancers: Orthodox PROTACs and beyond
    Jin Li, Xinxin Chen, Aiping Lü, Chao Liang · 2023 · The Innovation
13. Building ubiquitination machineries: E3 ligase multi-subunit assembly and substrate targeting by PROTACs and molecular glues
    Sarath Ramachandran, Alessio Ciulli · 2020 · Current Opinion in Structural Biology
14. Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma
    Lorraine N. Davis, Daniel W. Sherbenou · 2021 · Cancers
15. Unveiling the hidden interactome of CRBN molecular glues
    Kheewoong Baek, Rebecca J. Metivier, Shourya S. Roy Burman, Jonathan W. Bushman, Hojong Yoon, Ryan J. Lumpkin, Julia K. Ryan, Dinah M. Abeja, Megha Lakshminarayan, Hong Yue et al. · 2025 · Nature Communications
16. Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology
    Takumi Ito, Yuki Yamaguchi, Hiroshi Handa · 2021 · Cell chemical biology
17. Direct-to-biology, automated, nano-scale synthesis, and phenotypic screening-enabled E3 ligase modulator discovery
    Zefeng Wang, Shabnam Shaabani, Xiang Gao, Yuen Lam Dora Ng, Valeriia Sapozhnikova, Philipp Mertins, Jan Krönke, Alexander S. S. Dömling · 2023 · Nature Communications
18. UM171 glues asymmetric CRL3–HDAC1/2 assembly to degrade CoREST corepressors
    Yeo, Megan J. R., Zhang, Olivia, Xie, Xiaowen, Nam, Eunju, Payne, N. Connor, Gosavi, Pallavi M., Kwok, Hui Si, Iram, Irtiza, Lee, Ceejay, Li, Jiaming et al. · 2025 · Nature
19. E3 ligase ligand optimization of Clinical PROTACs
    Hanrui Jiang, Huan Xiong, Shuang-Xi Gu, Mingliang Wang · 2023 · Frontiers in Chemistry
20. Orphan quality control shapes network dynamics and gene expression
    Kevin G. Mark, SriDurgaDevi Kolla, Jacob D. Aguirre, Danielle M. Garshott, Stefan Schmitt, Diane L. Haakonsen, Christina Xu, Lukas Kater, Georg Kempf, Brenda Martínez-González et al. · 2023 · Cell
21. Targeting cereblon in hematologic malignancies
    Fuchs, Ota · 2023 · Blood Reviews
22. Profiling the Landscape of Drug Resistance Mutations in Neosubstrates to Molecular Glue Degraders
    Gosavi, Pallavi M., Ngan, Kevin C., Yeo, Megan J. R., Su, Cindy, Li, Jiaming, Lue, Nicholas Z., Hoenig, Samuel M., Liau, Brian B. · 2022 · ACS Central Science
23. Machine Learning Modeling of Protein-Intrinsic Features Predicts Tractability of Targeted Protein Degradation
    Zhang, Wubing, Roy Burman, Shourya S., Chen, Jiaye, Donovan, Katherine A., Cao, Yang, Shu, Chelsea, Zhang, Boning, Zeng, Zexian, Gu, Shengqing, Zhang, Yi et al. · 2022 · Genomics, Proteomics & Bioinformatics
24. Clues to molecular glues
    Thomas M. Geiger, Sabine C. Schäfer, Johannes Kilian Dreizler, Michael Walz, Felix Hausch · 2021 · Current Research in Chemical Biology
25. Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell lines
    Nishiguchi, Gisele, Mascibroda, Lauren G., Young, Sarah M., Caine, Elizabeth A., Abdelhamed, Sherif, Kooijman, Jeffrey J., Miller, Darcie J., Das, Sourav, McGowan, Kevin, Mayasundari, Anand et al. · 2024 · Nature Communications
26. Nucleic-Acid-Based Targeted Degradation in Drug Discovery
    Wei Wang, Shipeng He, Guoqiang Dong, Chunquan Sheng · 2022 · Journal of Medicinal Chemistry
27. Novel approaches to targeted protein degradation technologies in drug discovery
    Yu Xue, Andrew A. Bolinger, Jia Zhou · 2023 · Expert Opinion on Drug Discovery
28. Targeting post-translational modification of transcription factors as cancer therapy
    Qian, Meijia, Yan, Fangjie, Yuan, Tao, Yang, Bo, He, Qiaojun, Zhu, Hong · 2020 · Drug Discovery Today
29. Functional genomics uncovers the transcription factor BNC2 as required for myofibroblastic activation in fibrosis
    Marie Bobowski, Clémence Boulet, Francesco Paolo Zummo, Julie Dubois‐Chevalier, Céline Gheeraert, Mohamed Bou Saleh, Jean‐Marc Strub, Amaury Farce, Maheul Ploton, Loïc Guille et al. · 2022 · Nature Communications
30. A critical evaluation of the approaches to targeted protein degradation for drug discovery
    Chopra, Rajesh, Sadok, Amine, Collins, Ian · 2019 · Drug Discovery Today: Technologies
31. Safety switches for adoptive cell therapy
    Ali Can Sahillioğlu, Ton N. Schumacher · 2021 · Current Opinion in Immunology
32. Dual IKZF2 and CK1α degrader targets acute myeloid leukemia cells
    Park, Sun-Mi, Miyamoto, David K., Han, Grace Y.Q., Chan, Mandy, Curnutt, Nicole M., Tran, Nathan L., Velleca, Anthony, Kim, Jun Hyun, Schurer, Alexandra, Chang, Kathryn et al. · 2023 · Cancer Cell
33. Safety and efficacy of thalidomide in patients with transfusion-dependent β-thalassemia: a randomized clinical trial
    Jiangming Chen, Weijian Zhu, Jie Liu, Guizhen Wang, Xiaoqin Chen, Yun Tan, Weiwei Xu, Li-Wei Qu, Jinyan Li, Huan-Ju Yang et al. · 2021 · Signal Transduction and Targeted Therapy
34. Systematic profiling of conditional degron tag technologies for target validation studies
    Daniel P. Bondeson, Zachary Mullin-Bernstein, Sydney Oliver, Thomas A. Skipper, Thomas C. Atack, Nolan R. Bick, Meilani Ching, Andrew A. Guirguis, Jason J. Kwon, Carly R. Langan et al. · 2022 · Nature Communications
35. Proteomic characterization of post-translational modifications in drug discovery
    Linhui Zhai, Kai‐Feng Chen, Bingbing Hao, Minjia Tan · 2022 · Acta Pharmacologica Sinica
36. Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence
    Duran-Frigola, Miquel, Cigler, Marko, Winter, Georg E. · 2023 · Journal of the American Chemical Society
37. Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface
    Mingxing Teng, Scott B. Ficarro, Hojong Yoon, Jianwei Che, Jing Zhou, Eric S. Fischer, Jarrod A. Marto, Tinghu Zhang, Nathanael S. Gray · 2020 · ACS Medicinal Chemistry Letters
38. Avadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic Malignancies
    Aline Renneville, Jessica A. Gasser, Daniel E. Grinshpun, Pierre M. Jean Beltran, Namrata D. Udeshi, Mary E. Matyskiela, Thomas Clayton, Marie E. McConkey, Kaushik Viswanathan, Alexander Tepper et al. · 2021 · Blood Cancer Discovery
39. Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation
    Camilla Ruffilli, Sascha Röth, Monica Rodrigo, Helen Boyd, Noam Zelcer, Kévin Moreau · 2022 · ACS Pharmacology & Translational Science
40. Identification and structural basis of C-terminal cyclic imides as natural degrons for cereblon
    Heim, Christopher, Spring, Anna-Katharina, Kirchgäßner, Sören, Schwarzer, Dirk, Hartmann, Marcus D. · 2022 · Biochemical and Biophysical Research Communications
41. The cyclimids: Degron-inspired cereblon binders for targeted protein degradation
    Saki Ichikawa, N. Connor Payne, Wenqing Xu, Chia‐Fu Chang, Nandini Vallavoju, Spencer Frome, Hope A. Flaxman, Ralph Mazitschek, Christina M. Woo · 2024 · Cell chemical biology
42. Emerging Roles of SKP2 in Cancer Drug Resistance
    Ting Wu, Xinsheng Gu, Hongmei Cui · 2021 · Cells
43. Design of a Cereblon construct for crystallographic and biophysical studies of protein degraders
    Kroupova, Alena, Spiteri, Valentina A., Rutter, Zoe J., Furihata, Hirotake, Darren, Darren, Ramachandran, Sarath, Chakraborti, Sohini, Haubrich, Kevin, Pethe, Julie, Gonzales, Denzel et al. · 2024 · Nature Communications
44. Decrypting the molecular basis of cellular drug phenotypes by dose-resolved expression proteomics
    Stephan Eckert, Nicola Berner, Karl Kramer, Annika Schneider, Julian Müller, Severin Lechner, Sarah Brajkovic, Amirhossein Sakhteman, Christian Grätz, Jonas Fackler et al. · 2024 · Nature Biotechnology
45. Mechanisms of lenalidomide sensitivity and resistance
    Sergio Martínez-Høyer, Aly Karsan · 2020 · Experimental Hematology
46. Cereblon Modulators Target ZBTB16 and Its Oncogenic Fusion Partners for Degradation via Distinct Structural Degrons
    Mary E. Matyskiela, Jin‐Yi Zhu, Joshua M. Baughman, Thomas Clayton, Michelle Slade, Hon Kit Wong, Kristina Danga, Xinde Zheng, Mark Labow, Laurie A. LeBrun et al. · 2020 · ACS Chemical Biology
47. Targeting oncoproteins with a positive selection assay for protein degraders
    Koduri, Vidyasagar, Duplaquet, Leslie, Lampson, Benjamin L., Wang, Adam C., Sabet, Amin H., Ishoey, Mette, Paulk, Joshiawa, Teng, Mingxing, Harris, Isaac S., Endress, Jennifer E. et al. · 2021 · Science Advances
48. Emerging strategies for prospective discovery of molecular glue degraders
    Baiyun Wang, Shiyun Cao, Ning Zheng · 2024 · Current Opinion in Structural Biology
49. Small-Molecule Approaches to Targeted Protein Degradation
    Tyler B. Faust, Katherine A. Donovan, Hong Yue, Philip P. Chamberlain, Eric S. Fischer · 2020 · Annual Review of Cancer Biology
50. Quality control of protein complex composition
    Chris Padovani, Predrag Jevtić, Michael Rapé · 2022 · Molecular Cell
51. A Comprehensive Overview of Small-Molecule Androgen Receptor Degraders: Recent Progress and Future Perspectives
    Si Ha, Guoshun Luo, Hua Xiang · 2022 · Journal of Medicinal Chemistry
52. Routes to molecular glue degrader discovery
    Yanfen Liu, Jieyun Bai, Dong Li, Yong Cang · 2025 · Trends in Biochemical Sciences
53. Alkylamine-tethered molecules recruit FBXO22 for targeted protein degradation
    Chrysanthi Kagiou, Jose Antonio Cisneros, Jakob Farnung, Joanna Liwocha, Fabian Offensperger, Kevin D. Dong, Ka Yang, Gary Tin, Christina S. Horstmann, Matthias Hinterndorfer et al. · 2024 · Nature Communications
54. Lessons learned in linking PROTACs from discovery to the clinic
    Andy Pike, Esther C. Y. Lee, Iacovos N. Michaelides, Markus Schade, Ankit Sharma, James S. Scott, Abhishek Srivastava · 2025 · Nature Reviews Chemistry
55. The novel cereblon modulator CC-885 inhibits mitophagy via selective degradation of BNIP3L
    Bingbing Hao, Xiaojing Li, Xinglong Jia, Yuxing Wang, Linhui Zhai, Duanzhuo Li, Jie Liu, Die Zhang, Yu-Lu Chen, Yonghu Xu et al. · 2020 · Acta Pharmacologica Sinica
56. Ubiquitination and degradation of SUMO1 by small-molecule degraders extends survival of mice with patient-derived tumors
    Bellail, Anita C., Jin, Hong Ri, Lo, Ho-Yin, Jung, Sung Han, Hamdouchi, Chafiq, Kim, Daeho, Higgins, Ryan K., Blanck, Maximilian, le Sage, Carlos, Cross, Benedict C.S. et al. · 2021 · Science Translational Medicine
57. E3-Specific Degrader Discovery by Dynamic Tracing of Substrate Receptor Abundance
    Alexander Hanzl, Eleonora Barone, Sophie Bauer, Hong Yue, Radosław P. Nowak, Elisa Hahn, Eugenia V. Pankevich, Anna Koren, Stefan Kubicek, Eric S. Fischer et al. · 2023 · Journal of the American Chemical Society
58. Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias
    Ricardo De Matos Simoes, Ryosuke Shirasaki, Sondra L. Downey-Kopyscinski, Geoffrey M. Matthews, Benjamin G. Barwick, Vikas Anand Gupta, Daphné Dupéré-Richer, Shizuka Yamano, Yiguo Hu, Michal Sheffer et al. · 2023 · Nature Cancer
59. Identification and selectivity profiling of small-molecule degraders via multi-omics approaches
    Natalie S. Scholes, Cristina Mayor‐Ruiz, Georg E. Winter · 2021 · Cell chemical biology
60. Genomic characterization of functional high-risk multiple myeloma patients
    Cinnie Yentia Soekojo, Tae‐Hoon Chung, Mohammad Shaheryar Furqan, Wee Joo Chng · 2022 · Blood Cancer Journal
61. Development of Photolenalidomide for Cellular Target Identification
    Zhi Lin, Yuka Amako, Farah Kabir, Hope A. Flaxman, Bogdan Budnik, Christina M. Woo · 2022 · Journal of the American Chemical Society
62. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery
    Jiayue Xi, Ruyue Zhang, Ke Chen, Lin Yao, Muqiong Li, Ru Jiang, Xiaoye Li, Li Fan · 2022 · Bioorganic Chemistry
63. Structural rationalization of GSPT1 and IKZF1 degradation by thalidomide molecular glue derivatives
    Radosław P. Nowak, Jianwei Che, Silas Ferrao, Nikki R. Kong, Hu Liu, Breanna L. Zerfas, Lyn H. Jones · 2023 · RSC Medicinal Chemistry
64. Next steps for targeted protein degradation
    Mackenzie W. Krone, Craig M. Crews · 2024 · Cell chemical biology
65. Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera
    Kidae Kim, Dong-Ho Lee, Sungryul Park, Seung-Hyun Jo, Bonsu Ku, Sung Goo Park, Byoung Chul Park, Yeong Uk Jeon, Sunjoo Ahn, Chung Hyo Kang et al. · 2019 · Scientific Reports
66. A “Golden Age” for the discovery of new antileishmanial agents: Current status of leishmanicidal gold complexes and prospective targets beyond the trypanothione system
    Letícia B. Rosa, Rochanna Luane Aires Lima, Laiane dos Santos Oliveira, Josielle V. Fontes, Danilo Ciccone Miguel, Camilla Abbehausen · 2021 · ChemMedChem
67. Inhibitors, PROTACs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin-Dependent Kinase
    Sandeep Rana, Jayapal Reddy Mallareddy, Sarbjit Singh, Lidia Boghean, Amarnath Natarajan · 2021 · Cancers
68. Targeted protein degraders march towards the clinic for neurodegenerative diseases
    Dhiraj Kumar, Md. Imtaiyaz Hassan · 2022 · Ageing Research Reviews
69. A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer
    Lifeng Li, Wenhua Xue, Zhibo Shen, Jie Liu, Min Hu, Zhenyong Cheng, Yuxing Wang, Yulu Chen, Hao Chang, Yingyi Liu et al. · 2020 · Molecular Therapy — Oncolytics
70. Light-Controllable PROTACs for Temporospatial Control of Protein Degradation
    Jing Liu, Yunhua Peng, Wenyi Wei · 2021 · Frontiers in Cell and Developmental Biology
71. SALL Proteins; Common and Antagonistic Roles in Cancer
    Álvarez, Claudia, Quiroz, Aracelly, Benítez-Riquelme, Diego, Riffo, Elizabeth, Castro, Ariel F., Pincheira, Roxana · 2021 · Cancers
72. Exploration of the tunability of BRD4 degradation by DCAF16 trans-labelling covalent glues
    Muhammad Murtaza Hassan, Yen-Der Li, Michelle W. Ma, Mingxing Teng, Woong Sub Byun, Kedar Puvar, Ryan J. Lumpkin, Brittany Sandoval, Justine C. Rutter, Cyrus Y. Jin et al. · 2024 · European Journal of Medicinal Chemistry
73. Induced proximity-based therapeutic modalities
    Elizabeth A. King, Margot Meyers, Daniel K. Nomura · 2025 · Nature Reviews Drug Discovery
74. Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4
    David G. Belair, Gang Lu, Laura E. Waller, Jason A. Gustin, Nathaniel D. Collins, Kyle L. Kolaja · 2020 · Scientific Reports
75. Emerging Trends in Cancer Drug Discovery—From Drugging the “Undruggable” to Overcoming Resistance
    Joachim Rudolph, Jeff Settleman, Shiva Malek · 2021 · Cancer Discovery
76. Linkage-specific ubiquitin chain formation depends on a lysine hydrocarbon ruler
    Joanna Liwocha, David T. Krist, Gerbrand J. van der Heden van Noort, Fynn M. Hansen, Vinh H. Truong, Özge Karayel, Nicholas Purser, Daniel Houston, Nicole Burton, Mark J. Bostock et al. · 2020 · Nature Chemical Biology
77. Ubiquitin-dependent regulation of transcription in development and disease
    Kevin G. Mark, Michael Rapé · 2021 · EMBO Reports
78. Molecular glue degraders: exciting opportunities for novel drug discovery
    Lemaitre, Thomas, Cornu, Marie, Schwalen, Florian, Since, Marc, Kieffer, Charline, Voisin-Chiret, Anne Sophie · 2024 · Expert Opinion on Drug Discovery
79. SALL4: An Intriguing Therapeutic Target in Cancer Treatment
    Moein, Shiva, Tenen, Daniel G., Amabile, Giovanni, Chai, Li · 2022 · Cells
80. DEGRONOPEDIA: a web server for proteome-wide inspection of degrons
    Szulc, Natalia A, Stefaniak, Filip, Piechota, Małgorzata, Soszyńska, Anna, Piórkowska, Gabriela, Cappannini, Andrea, Bujnicki, Janusz M, Maniaci, Chiara, Pokrzywa, Wojciech · 2024 · Nucleic Acids Research
81. CRL4CRBN E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma
    Joanna Barankiewicz, Aleksander Salomon‐Perzyński, Irena Misiewicz-Krzemińska, Ewa Lech‐Marańda · 2022 · Cancers
82. Applications of protein ubiquitylation and deubiquitylation in drug discovery
    Yilin Chen, Haoan Xue, Jianping Jin · 2024 · Journal of Biological Chemistry
83. Drug Discovery Approaches to Target E3 Ligases
    A. Rodríguez-Gimeno, Carles Galdeano · 2024 · ChemBioChem
84. A PROTAC targets splicing factor 3B1
    Rodrigo A. Gama-Brambila, Jie Chen, Jun Zhou, Georg Tascher, Christian Münch, Xinlai Cheng · 2021 · Cell chemical biology
85. Selectively targeting individual bromodomain: Drug discovery and molecular mechanisms
    Qianqian Wang, Xiaomin Shao, Elaine Lai‐Han Leung, Yingqing Chen, Xiaojun Yao · 2021 · Pharmacological Research
86. GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms
    Xiangrong Geng, Chenguang Wang, Xin Gao, Pinki Chowdhury, Jonathan Weiss, José A. Villegas, Badeia Saed, Thilini Perera, Ying Hu, John C. Reneau et al. · 2022 · Blood Cancer Journal
87. Targeted Protein Degradation: Design Considerations for PROTAC Development
    Nathan L. Tran, Georges A. Leconte, Fleur M. Ferguson · 2022 · Current Protocols
88. Identification and characterization of cancer vulnerabilities via targeted protein degradation
    Mayor-Ruiz, Cristina, Winter, Georg E. · 2019 · Drug Discovery Today: Technologies
89. Physicochemistry of Cereblon Modulating Drugs Determines Pharmacokinetics and Disposition
    Nikki R. Kong, Hu Liu, Jianwei Che · 2021 · ACS Medicinal Chemistry Letters
90. An IMiD-induced SALL4 degron system for selective degradation of target proteins
    Yamanaka, Satoshi, Shoya, Yuki, Matsuoka, Saya, Nishida-Fukuda, Hisayo, Shibata, Norio, Sawasaki, Tatsuya · 2020 · Communications Biology
91. Targeted Protein Degradation: Clinical Advances in the Field of Oncology
    Abdelrahman K. A. A. Salama, Marija V. Trkulja, Emilio Casanova, Iris Z. Uras · 2022 · International Journal of Molecular Sciences
92. Discovery of Molecular Glue Degraders via Isogenic Morphological Profiling
    Amanda Ng, Fabian Offensperger, Jose Antonio Cisneros, Natalie S. Scholes, Monika Malik, Ludovica Villanti, Andrea Rukavina, Evandro Ferrada, J. Thomas Hannich, Anna Koren et al. · 2023 · ACS Chemical Biology
93. Protein degraders - from thalidomide to new PROTACs
    Takumi Ito · 2023 · The Journal of Biochemistry
94. An Automated Electrochemical Flow Platform to Accelerate Library Synthesis and Reaction Optimization
    Eduardo Rial‐Rodríguez, Jason D. Williams, David Cantillo · 2024 · Angewandte Chemie International Edition
95. Lenalidomide Stabilizes Protein–Protein Complexes by Turning Labile Intermolecular H-Bonds into Robust Interactions
    Marina Miñarro-Lleonar, Andrea Bertran‐Mostazo, Jorge Duro, Xavier Barril, Jordi Juárez‐Jiménez · 2023 · Journal of Medicinal Chemistry
96. Unbiased mapping of cereblon neosubstrate landscape by high-throughput proteomics
    Steger, Martin, Nishiguchi, Gisele, Wu, Qiong, Schwalb, Bjoern, Shashikadze, Bachuki, McGowan, Kevin, Actis, Marisa, Aggarwal, Anup, Shi, Zhe, Price, Jeanine et al. · 2025 · Nature Communications
97. Impact of the Protein Data Bank on antineoplastic approvals
    John Westbrook, Rose Soskind, Brian P. Hudson, Stephen Kevin Burley · 2020 · Drug Discovery Today
98. A platform for the rapid synthesis of molecular glues (Rapid-Glue) under miniaturized conditions for direct biological screening
    Jingyao Li, Chunrong Li, Zhongrui Zhang, Zhen Zhang, Zhiping Wu, Junzhuo Liao, Zhen Wang, Meghan G. McReynolds, Haibo Xie, Le Guo et al. · 2023 · European Journal of Medicinal Chemistry
99. SuFEx-based chemical diversification for the systematic discovery of CRBN molecular glues
    Trever R. Carter, Natalia Milosevich, Lucas Dada, James B. Shaum, Karl Barry Sharpless, Seiya Kitamura, Michael A. Erb · 2024 · Bioorganic & Medicinal Chemistry
100. Unifying Catalysis Framework to Dissect Proteasomal Degradation Paradigms
     Rodriguez-Rivera, Frances P., Levi, Samuel M. · 2021 · ACS Central Science